ClinicalTrials.gg
CompletedNCT02727751T3MPO-3Updated Sep 9, 2020Results posted

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

A Phase 3 interventional study of Tenapanor in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
5th of 11
312 · median 186
Started
2016
the only one that year
Phase 3
7 of 11
2 open now
Registered
5th of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 5th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.

Read the detailed description

During the treatment period of up to 39-weeks, subjects will return for study visits approximately every 13 weeks. Subjects will undergo safety assessments at these visits, which may include a physical exam, ECG, vital signs, and clinical labs. Adverse events and concomitant medications will be recorded. Medication compliance will be monitored and the subjects will be given additional study drug as appropriate.

03

Conditions studied

  • Constipation Predominant Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects completed all 16 weeks of TEN-01-301 or all 26 weeks of TEN-01-302
  • Subject demonstrated adequate compliance with the study procedures during either the TEN-01-301 or TEN-01-302 studies
  • Females must be of non-; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of
  • Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization

Exclusion criteria

Exclusion Criteria:

  • Subject has been withdrawn or discontinued prematurely from either TEN-01-301 or TEN-01-302
  • The subject reports using any prohibited medication and is not willing to abide by the restrictions for intake
  • Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    50mg BID

    Tenapanor, 50 mg BID (100 mg total)

    Drug: Tenapanor

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events in >2% Patients

    Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams

    Time frame: 52-55 weeks

07

Results

Posted Apr 24, 2020

Participant flow

Participant flow — Overall Study
Milestone50mg BID
Started312
Completed262
Not completed50

Outcome measures

PrimaryAdverse Events in >2% Patients

Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams

Time frame:
52-55 weeks
Reported as:
Number · participants
Adverse Events in >2% Patients
participants50mg BID
Diarrhea33
Flatulence7
Upper Respiratory Tract Infection7
Headache11

Adverse events

Collected over This was an extension study that ran for up to 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50mg BID0/312 (0%)3/312 (1%)33/312 (10.6%)
Most frequent serious events
Most frequent serious events
Event50mg BID
LeukocytosisBlood and lymphatic system disorders1/312
Rib FractureInjury, poisoning and procedural complications1/312
EndometriosisReproductive system and breast disorders1/312
Most frequent other events
Most frequent other events
Event50mg BID
DiarrheaGastrointestinal disorders33/312

Baseline characteristics

Age, Continuous
Age, Continuous(years)50mg BID
Mean49.5 ± 13.15
Sex: Female, Male
Sex: Female, Male(Participants)50mg BID
Female255
Male57
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50mg BID
Hispanic or Latino130
Not Hispanic or Latino182
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50mg BID
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American89
White217
More than one race2
Unknown or Not Reported2
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)50mg BID
Mean29.98 ± 6.707
08

Study locations

1 site
  • Ardelyx Clinical Site
    Miami, Florida, United States
09

References and documents

Publications

  • Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056. PubMed 33337659 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Apr 5, 2016
Start
Mar 2016
Primary completionActual
Oct 2017
CompletionActual
Oct 2017
Results first posted
Apr 24, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02727751
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Apr 5, 2016
Start date
Mar 2016
Primary completion
Oct 2017
Completion
Oct 2017
Results posted
Apr 24, 2020
Last update
Sep 9, 2020

Study contacts

David P Rosenbaum, Ph.D.
study chair · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion